New FDA Approval for CML Patients

Asciminib (Scemblix) was recently approved for the following indications:

For patients with Philadelphia chromosome– positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors.

For patients with Ph+ CML in chronic phase with a T315I mutation

Here at Belong, we will continue to update you with new medical and research developments. If you are interested in clinical trial-related info or in participating in such a trial, you are invited to respond here or contact us in the “Find Clinical Trials” group.

Best of health,
The Clinical Trial Team

For more info:

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment

Doctor-Patient Relationship – a Partnership

The doctor-patient relationship should be a partnership, but frustration can set in when it’s not…

Understanding the Differences: MS, ALS, and Lou Gehrig’s Disease

Navigating through the world of neurological conditions can often feel like trying to find your…

Preparing for Chemotherapy

Preparing for chemotherapy can feel overwhelming, but planning and support can make a significant difference….

Is Dairy Bad for MS?

With so many opinions and studies floating around, it’s easy to feel like you’re in…

Loneliness and Cancer

A cancer diagnosis can bring intense feelings of isolation, as many patients feel that few…

Is Alcohol a Friend or Foe in Your MS Journey?

Navigating life with multiple sclerosis (MS) brings its own set of challenges and questions, especially…